metformina arena 500 mg
arena group s.a. - romania - metforminum - compr. - 500mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformina arena 850 mg
arena group s.a. - romania - metforminum - compr. - 850mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformina arena 1000 mg
arena group s.a. - romania - metforminum - compr. - 1000mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformin aurobindo 500 mg
milpharm limited - marea britanie - metforminum - compr. film. - 500mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformin aurobindo 850 mg
milpharm limited - marea britanie - metforminum - compr. film. - 850mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformin aurobindo 1000 mg
milpharm limited - marea britanie - metforminum - compr. film. - 1000mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformin aurobindo 1000 mg
apl swift services (malta) limited - malta - metforminum - compr. film. - 1000mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformin aurobindo 500 mg
apl swift services (malta) limited - malta - metforminum - compr. film. - 500mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
metformin aurobindo 850 mg
apl swift services (malta) limited - malta - metforminum - compr. film. - 850mg - antidiabetice orale si parenterale, exclusiv insuline biguanide
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetul zaharat, tip 2 - medicamente utilizate în diabet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 și 5. 1 pentru datele disponibile pe diferite combinații).